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Structural and Biochemical Characterization of Rm3, a Subclass B3
Metallo--Lactamase Identified from a Functional Metagenomic Study
Ramya Salimraj,a Lihong Zhang,b* Philip Hinchliffe,a Elizabeth M. H. Wellington,b Jürgen Brem,c Christopher J. Schoﬁeld,c
William H. Gaze,b* James Spencera
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdoma; School of Life Sciences, University of Warwick, Coventry, United Kingdomb;
Department of Chemistry, University of Oxford, Oxford, United Kingdomc
-Lactamase production increasingly threatens the effectiveness of -lactams, which remain a mainstay of antimicrobial chemo-
therapy. New activities emerge through both mutation of previously known -lactamases andmobilization from environmental
reservoirs. The spread of metallo--lactamases (MBLs) represents a particular challenge because of their typically broad-spec-
trum activities encompassing carbapenems, in addition to other -lactam classes. Increasingly, genomic andmetagenomic stud-
ies have revealed the distribution of putative MBLs in the environment, but in most cases their activity against clinically relevant
-lactams and, hence, the extent to which they can be considered a resistance reservoir remain uncharacterized. Here we charac-
terize the product of one such gene, blaRm3, identified through functional metagenomic sampling of an environment with high
levels of biocide exposure. blaRm3 encodes a subclass B3 MBL that, when expressed in a recombinant Escherichia coli strain, is
exported to the bacterial periplasm and hydrolyzes clinically used penicillins, cephalosporins, and carbapenems with an effi-
ciency limited by highKm values. An Rm3 crystal structure reveals the MBL superfamily / fold, which more closely resem-
bles that in mobilized B3MBLs (AIM-1 and SMB-1) than other chromosomal enzymes (L1 or FEZ-1). A binuclear zinc site sits in
a deep channel that is in part defined by a relatively extended N terminus. Structural comparisons suggest that the steric con-
straints imposed by the N terminus may limit its affinity for -lactams. Sequence comparisons identify Rm3-like MBLs in nu-
merous other environmental samples and species. Our data suggest that Rm3-like enzymes represent a distinct group of B3
MBLs with a wide distribution and can be considered an environmental reservoir of determinants of -lactam resistance.
The continued efficacy of -lactam antibiotics is threatened bythe dissemination of -lactamases, hydrolytic enzymes that
inactivate these important drugs by cleavage of the scissile -lac-
tam amide bond (1). In the 70 years since -lactams were first
introduced into the clinic, repeated mobilizations of -lactamase
genes from a variety of bacterial sources have led to their rapid
propagation in opportunistic Gram-negative pathogens, such as
the Enterobacteriaceae and nonfermenting species, including
Pseudomonas aeruginosa and Acinetobacter baumannii (2). Nota-
bly, some of the most successful -lactamases, in particular, the
CTX-M extended-spectrum -lactamase (ESBL), which is associ-
ated with resistance to third-generation cephalosporins, such as
cefotaxime, andwhich is nowdistributedworldwide (3), find their
origins in environmental organisms, illustrating how transfer of
antibiotic resistance genes from environmental to pathogenic spe-
cies can have profound clinical consequences (4). In the case of
CTX-M enzymes, it is now accepted that these originated inKluy-
vera spp. (5, 6), which are Gram-negative rod bacteria that are
found in both the human intestinal microbiome and the wider
natural environment (7).
-Lactamases are divided, primarily on the basis of their amino
acid sequences, into four main classes (8). Of these, three (classes
A, C, and D) are active-site nucleophilic serine -lactamases
(SBLs), and the remaining class, class B, consists of zinc met-
alloenzymes that are structurally andmechanistically unrelated to
the SBLs. The metallo--lactamases (MBLs) are themselves di-
vided into a further three groups (B1, B2, and B3) on the basis of
sequence differences that aremanifest as variations in the number
(1 or 2) of zinc ions required for full activity and as structural
differences that include variations in the coordination of the ac-
tive-site zinc ions (9, 10). MBLs are a growing clinical concern, as
they effectively hydrolyze all -lactam classes except the mono-
bactams and escape the action of SBL inhibitors (11) that are ap-
proved (clavulanate, tazobactam) or close to being approved
(avibactam, relebactam) for use in the clinic. B1MBLs, such as the
NDM (12) and VIM (13) enzymes, are now encountered with
increasing frequency on mobile genetic elements in organisms
such as Escherichia coli, Klebsiella pneumoniae, P. aeruginosa and
A. baumannii.
While B3 family members, such as AIM-1 (14) and SMB-1
(15), have been identified on mobile genetic elements, the major-
ity of these enzymes are chromosomal. However, in addition to
their presence in opportunist pathogens, such as Stenotrophomo-
nas maltophilia (16) and Elizabethkingia meningosepticum (17),
the B3 MBLs also have a very wide distribution in environmental
organisms and sequences. Compared to the B1 enzymes, the B3
MBLs are less well studied, display a greater degree of structural
and sequence diversity, and are more closely related to other
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branches of the wider metallohydrolase superfamily to which the
MBLs belong (18). Investigations of B3 MBLs from environmen-
tal sources will thus expand our understanding of activity and
structure within this group of enzymes and provide insights into
the nature of MBLs in the environment and the extent to which
such enzymes provide a reservoir of determinants of resistance to
the most clinically important -lactam antibiotics. Furthermore,
identifying how the distribution of such sequences changes in re-
sponse to human activity (i.e., exposure to antimicrobials within
the environment) can also provide evidence of the effect of human
activity upon the environmental resistance reservoir (19).
Technological advances have transformed our ability to sam-
ple and identify antibiotic resistance genes in the natural environ-
ment. In particular, combining sequence-based methodologies
(metagenomics) with functional methodologies (construction
and analysis of large libraries) can both establish the prevalence
and distribution of putative resistance genes and identify those
that confer a resistance phenotype, i.e., that are able to alter anti-
biotic susceptibility in a model organism (e.g., E. coli) (20–22).
This study provides a biochemical and structural characterization
of a B3MBL, Rm3, that was identified by application of this func-
tional metagenomics approach to study the distribution of deter-
minants of resistance to third-generation cephalosporins in envi-
ronmental sources selected on the basis of different degrees of
human impact. (Full details of the identification of Rm3 will be
presented elsewhere.) The blaRm3 gene (GenBank accession no.
KF485393.2) was isolated from a metagenomic library derived
from soil from a reed bed used to bioremediate effluent from a
textile mill with high levels of usage of quaternary ammonium
compounds (QACs). Screening of this library identified blaRm3 to
be one of a number of novel-lactamase genes able to decrease the
susceptibility of recombinant E. coli strains to third-generation
cephalosporins.
The amino acid sequence of Rm3 (Fig. 1) most closely re-
FIG 1 Sequence alignment of subclass B3 metallo--lactamases. Alignment of selected subclass B3 MBLs. Sequences were aligned using the Clustal Omega
program (66). Invariant residues are highlighted with a red background, and conservative substitutions (positions boxed) are in red text. Residue numbering is
according to the BBL standard numbering scheme (52); discontinuities (e.g., between residues 5 and 70, 80 and 90, and 150 and 170) are due to omission from
the figure of otherMBL subclasses. Secondary structure assignments (Dictionary of Protein Secondary Structure [67]) are from the Rm3 structure (this work). Red
triangles, zinc binding residues. Cysteine pair 208 and 213 and cysteine pair 256 and 290 are labeled 1 and 2, respectively. The positions of key Rm3 residues and
of Rm3 loops 1 and 2 are labeled below the alignment. This figure was prepared using the EsPript program (68).
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sembles that of other putative B3 MBLs from environmental
bacteria, in particular, sequences from the soil bacterium Jan-
thinobacterium (e.g., GenBank accession no. KKO63914.1; 89%
sequence identity [23]) and Solimonas spp. (e.g., NCBI accession
no. WP_020650668.1; 56% identity). Rm3 also resembles (54%
sequence identity) anovelB3MBL,LRA-8, identified fromameta-
genomics study of the Tanana river in central Alaska (20) (Fig. 1)
and a related sequence (GenBank accession no. AIA12579.1; 56%
identity) identified from a grassland soil sample fromMinnesota,
USA, as part of a functional metagenomics study of environmen-
tal antibiotic resistance genes (24). Of the biochemically charac-
terized B3 MBLs, Rm3 shares the highest sequence identity with
THIN-B (25) (49%) and is between 43% (SMB-1) (15) and 27%
(BJP-1) (26) identical to enzymes of known structure. On this
basis (Fig. 1 and 2), Rm3 can be considered a representative of a
group of uncharacterized novel B3MBLs that appear to be widely
distributed within the environmental microbiome. Here we pres-
ent the biochemical and structural characterization of recombi-
nant Rm3.
MATERIALS AND METHODS
Identification of blaRm3. Full details of the identification of Rm3 will be
presented elsewhere. Briefly, core samples were obtained from reed beds
used for the remediation of effluent from a textile mill in Yorkshire,
UnitedKingdom(27), and totalDNAwas purified as previously described
(21). Ametagenomic library was generated by cloning purifiedDNA frag-
ments into plasmid pCF430 (28) and transforming into E. coli strain
EC100 (Epicentre, MadisonWI, USA) by electroporation. Recombinants
were passaged over 10 to 20 generations, and clones resistant to third-
generation cephalosporins were selected by plating on ceftazidime (1 g/
ml). Putative resistance genes were identified by sequencing positive
clones, and their contribution to the resistance phenotype was confirmed
by inactivation using transposon mutagenesis (EZ-Tn5 kit; Epicentre),
allowing selection by loss of phenotype (21).
MIC determination for metagenomic clones.MIC values for metag-
enomic clones were determined by agar dilution on Iso-Sensitest agar
(Oxoid) with an inoculum of 105 CFU per spot (29).
Recombinant Rm3 expression and purification. The complete Rm3
open reading frame (including the putative periplasmic export sequence)
was amplified frommetagenomic clone Rm3 by PCR with primers RM3F
(AAGGCATATGATGTCCCTCACACCACCACGCGCG) and RM3R2
(AATGGGATCCTTACTGCTGTTTTTCCTGGT)with proofreading Pfu
DNA polymerase. The product was ligated into the T7 expression vector
pET26b (30) using theNdeI and BamHI restriction sites, and the integrity
of the resulting plasmid, pLHZRM3, was confirmed by DNA sequencing.
E. coli ArcticExpress(DE3) competent cells (Agilent, Stockport, United
Kingdom) transformed with pLHZRM3 were grown (at 30°C with shak-
ing at 160 rpm in Power Broth [Athena Enzyme Systems, Baltimore, MD,
USA]) to an optical density at 600 nm of 0.6, and expression was in-
duced overnight (1 mM isopropyl--D-thiogalactopyranoside [Melford
Laboratories, Ipswich, United Kingdom], 13°C). Cells were harvested by
centrifugation (7,205 g, 30 min, 4°C) and lysed in a Constant Systems
(Daventry, United Kingdom) cell disruptor (25,000 lb/in2). Debris was
removed by centrifugation (38,724  g, 1 h), and the supernatant was
exchanged into buffer A (50 mM potassium phosphate, pH 7.0, 1 M am-
monium sulfate) by extensive dialysis using a 3,000-Da-cutoff membrane
(Medicell International, London, United Kingdom).
Protein for crystallography was purified by the following method.
Twenty milliliters of the dialysate was loaded on a 1-ml Phenyl Sepharose
fast-flow (FF) high-sub (HS) column (GE Healthcare Life Sciences, Little
Chalfont, United Kingdom), and the column was washed consecutively
with buffer B (buffer A plus 10 mMMgCl2, 5 mMATP, 50 mMKCl) and
buffer A prior to elution on a gradient of 0 to 50% buffer C (50 mM
potassium phosphate, pH 7.0). Rm3-containing fractions were identified
by SDS-PAGE (31) and concentrated to a volume of2ml by centrifugal
ultrafiltration using an Amicon concentrator with a 3,000-Da-molecular-
mass cutoff (Millipore, Watford, United Kingdom). Protein was loaded
onto a 300-ml Superdex S75 size exclusion column (GE Healthcare) and
eluted at a flow rate of 1ml/min in buffer D (20mMTris, pH 7.5, 200mM
NaCl). Rm3-containing fractions were pooled and concentrated as de-
scribed above.
For enzyme kinetic experiments, Rm3 was purified by a modified ver-
sion of the protocol described above, where recombinant protein was
produced in E. coli SoluBL21 cells (AMS Biotechnology, Abingdon,
United Kingdom) that were grown overnight in autoinduction Terrific
broth (Formedium, Hunstanton, United Kingdom) at 25°C. The hydro-
phobic interaction chromatography step utilized a 40-ml Phenyl Sephar-
ose FF HS column, omitted the ATP wash, and eluted bound protein on a
0 to 100% buffer C gradient; and size exclusion chromatography utilized
a 120-ml HiLoad 16/60 Superdex 75 pg column (GE Healthcare).
Verification of recombinant Rm3 by mass spectrometry. Electros-
pray ionization mass analyses were performed (as described previously
[32]) in the positive ion mode using a Waters (Elstree, United Kingdom)
LCT Premier instrument equipped with a time of flight (TOF) analyzer.
An LCT Premier mass spectrometer (Waters) was coupled to an Agilent
1100 series high-performance liquid chromatograph (HPLC) using a
Chromolith FastGradient RP-18 end-capped column equipped with a
50-2 HPLC column made of monolithic silica (C-18; 2 by 50 mm; mac-
ropore diameter, 1.6m;Merck, Beeston, United Kingdom). The instru-
ment was connected to a CTC autosampler inlet system. A multistep
gradient (solvent A, 94.9% H2O, 5% acetonitrile [CH3CN], and 0.1%
formic acid; solvent B, 99.9% CH3CN and 0.1% formic acid; 0 to 1 min
5% solvent B for equilibration, followed by a linear gradient to 100%
solvent B over 4 min and then 100% solvent B for an additional 3 min,
followed by a linear gradient over 2 min back to 5% solvent B to reequili-
brate the column) was run over 10 min to separate the protein samples at
FIG 2 Phylogenetic tree of selected subclass B3 metallo--lactamases. Se-
quences were aligned using the Clustal Omega program (66), and the phylo-
genetic tree was visualized using the Drawgram (version 3.67) component of
the PHYLIP package (69).
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flow rates of 0.4 ml/min for the first 5 min and then 1.0 ml/min for the
remaining time. The electrospray ionization source used a capillary volt-
age of 3.2 kV and cone voltage of 25 V. Nitrogen was used as the nebulizer
and desolvation gas at a flow rate of 600 liters/h. Protein typically eluted as
a peak between 3 and 5 min under these conditions. Calculated masses
were obtained using the ExPasy ProtParam tool (http://web.expasy.org
/protparam/) (33).
Steady-state kinetics of -lactam hydrolysis by recombinant Rm3.
Hydrolysis of selected -lactams by recombinant Rm3 was investigated
under steady-state conditions. The buffer was 50 mM HEPES, pH 7.0,
supplemented with 100MZnCl2 and 100g/ml bovine serum albumin,
and the protein concentration was 10 nM. Measurements used either a
Polarstar Omega plate reader (BMG LabTech, Aylesbury, United King-
dom) or, for complete hydrolysis curves, a Lambda 35 spectrophotometer
(Perkin-Elmer, Seer Green, United Kingdom). The extinction coefficients
andwavelengths used (34)were as follows:775M1 cm1 at 235 nm for
penicillin G, 820 M1 cm1 at 235 nm for ampicillin, 7,700 M1
cm1 at 260 nm for cefoxitin, 9,000 M1 cm1 at 260 nm for ceftazi-
dime,7,500M1 cm1 at 260 nm for cefotaxime,6,500M1 cm1 at
300 nm for meropenem, 9,000 M1 cm1 at 300 nm for imipenem,
and700 M1 cm1 at 320 nm for aztreonam.
Data were analyzed by fitting to the Michaelis-Menten equation: V
kcat · [E] · [S]/(Km 	 [S]), where V is the measured initial velocity at
substrate concentration [S], and [E] is the concentration of enzyme.
Where high apparent Km values precluded data collection under the con-
ditions required to achieve saturation of the hydrolysis rate, the value of
kcat/Kmwas measured by fitting progress curves (absorbance versus time)
for a complete hydrolysis reaction to the following exponential: At 
A
	 (A0A
) · e
kt, whereAt is the absorbance at time t,A0 is the initial
absorbance, A
 is the final absorbance, and k is the first-order rate con-
stant. The observed first-order rate constant (k) was then (kcat/Km) · [E]
(35). Curve fitting was undertaken using Prism software (GraphPad, La
Jolla, CA, USA).
Rm3crystallization and structure determination.PurifiedRm3pro-
tein in buffer Dwas concentrated to13mg/ml by centrifugal ultrafiltra-
tion as described above and supplemented with 100MZnCl2 and 5mM
Tris(2-carboxyethyl)phosphine (TCEP) hydrochloride (Fisher Scien-
tific). Initial crystallization hits were obtained from commercial sparse
matrix screening kits (Proplex; Molecular Dimensions, Newmarket,
United Kingdom) (36) using a Phoenix crystallization robot (Art Robbins
Instruments, Sunnyvale, CA, USA) to set 100-nl plus 100-nl sitting drops
in 96-well MRC plates (Molecular Dimensions) using a reservoir volume
of 100l. Conditions were optimized using 1-l plus 1-l hanging drops
in 24-well XRL plates (Molecular Dimensions) with a 500-l reservoir
volume. Diffraction data were collected from a single crystal grown in a
hanging drop from 14% (wt/vol) polyethylene glycol 8000, 0.1MTris, pH
8, 0.15 M LiCl. All crystallization experiments were carried out at 18°C.
The Rm3 crystal was cryoprotected for30 s by exposure to reservoir
solution supplemented with 25% ethylene glycol, mounted in a Spine
standard pin (MolecularDimensions), and flash frozen in liquid nitrogen.
Diffraction data were collected on beamline I04 of the Diamond Light
Source (DLS), United Kingdom, using a Pilatus 6M-F detector. A total of
934 images of 0.15° oscillation (exposure, 0.15 s per image; beam intensity,
20%) were collected at a wavelength of 0.9795 Å. Diffraction data were
integrated using XDS (37), the space group was identified using Pointless
(38), and the data were scaled and merged using Aimless (38), as imple-
mented in the Xia2 pipeline (39). The structure was solved by molecular
replacement using Phaser (40), with Chainsaw (41) being used to create a
search model based upon S. maltophilia L1 (chain A of the structure with
PDB accession no. 2QDT [42]) by pruning side chains of nonidentical
amino acids to their C- atoms. Models were built in Coot (43), and
refinement was carried out using Refmac 5 (44). Final refinement and
model validation (MolProbity [45]) took place in Phenix (46).
Accession number(s). Coordinates and structure factors have been
deposited in the Protein Data Bank (PDB; www.rcsb.org/pdb) under ac-
cession no. 5IQK.
RESULTS AND DISCUSSION
Identification of Rm3 as a subclass B3 metallo--lactamase.
blaRm3 was identified by selecting ceftazidime-resistant clones
from ametagenomic library constructed fromDNApurified from
samples originating from a reed bed used to bioremediate effluent
from a textile mill with high levels of usage of quaternary ammo-
nium compounds (QACs). QACs are disinfective agents with
wide industrial application and have been implicated in the selec-
tion of co- and cross-resistance to a variety of antibiotic classes,
including-lactams (47, 48). blaRm3 was situated on an 8-kbDNA
fragment (metagenomic clone Rm3; GenBank accession no. KF4
85393.2) that exerted variable effects upon susceptibility to -lac-
tam antibiotics but that resulted in a 16-fold elevation of the MIC
of E. coli EC100 to ceftazidime compared to that for the vector-
only control (Table 1). This effect was abolished by insertional
inactivation of blaRm3 by transposition (data not shown). The
amino acid sequence of the blaRm3-encodedprotein, Rm3, showed
properties (the presence of a His116-X-His118-X-Asp120-His121
sequence motif and similarity to previously characterized en-
zymes) characteristic of a subclass B3 MBL (Fig. 1).
Expression and kinetic characterization of recombinant
Rm3. The blaRm3 gene encodes a 302-residue polypeptide that
includes an N-terminal leader peptide of 23 residues that was
identified by the SignalP program (49) to be a periplasmic export
sequence. The complete Rm3 open reading frame, including the
putative export sequence, was expressed in either E. coli ArcticEx-
press or SoluBL21 and was purified to apparent homogeneity by
hydrophobic interaction and size exclusion chromatography.
Quadrupole time of flight (QTOF) mass spectrometry under de-
naturing conditions gave a mass of 29,805 Da for the purified
protein, consistent with a predicted mass of 29,808.5 Da for the
Rm3 fragment resulting from removal of the predicted precursor
polypeptide after residue 23. Thus, these data confirm that the
leader peptide is removed from recombinant Rm3 by posttrans-
lational processing in E. coli and strongly indicate that, as is the
case for other-lactamases of Gram-negative bacteria, the protein
is exported to the bacterial periplasm.
TABLE 1 Effect of Rm3 expression on -lactam MICs for recombinant Escherichia coli EC100
Construct
MICc (g/ml)
AMP AMX CAR TMC ATM CTX CAZ IPM
pCF430a 8 8 32 16 0.25 0.25 0.5 0.5
pCF430-Rm3b 16 8 32 32 0.5 0.25 8 1
a Empty pCF430 in Escherichia coli EC100.
b pCF430 carrying an 8-kb Rm3 metagenomic fragment.
c AMP, ampicillin; AMX, amoxicillin; CAR, carbenicillin; TMC, temocillin; ATM, aztreonam; CTX, cefotaxime; CAZ, ceftazidime; IPM, imipenem.
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Steady-state kinetic experiments indicate that Rm3 is able to
hydrolyze a range of penicillin, cephalosporin, and carbapenem
antibiotics with various degrees of efficiency (Table 2). Notably, it
was possible to obtain accurate Km estimates for only two sub-
strates, meropenem and ampicillin, of the eight that were evalu-
ated. For the other substrates tested, it proved difficult to saturate
the Michaelis-Menten (i.e., rate-versus-substrate concentration)
plots, indicating high Km values and, likely, low affinity. For these
substrates, values for catalytic efficiency (kcat/Km) only are re-
ported. Overall catalytic efficiencies approaching 105 M1 s1
were achieved for substrates from all classes except the monobac-
tam aztreonam, against which Rm3, as is the case for other MBLs,
showed no hydrolytic activity. These data show Rm3, in common
withmost other B3MBLs, to be an enzymewith a broad spectrum
of activity. The relatively low catalytic efficiencies that are achieved
by Rm3 compared to those that are achieved by other character-
ized B3 MBLs, where values for kcat/Km in excess of 10
7 M1 s1
have been reported for some favorable enzyme-substrate combi-
nations (e.g., AIM-1-catalyzed imipenem hydrolysis [14]), arise
primarily from the relatively high Km values. For all substrates
tested, Km values were 10
4 M or above; in contrast, with most
other B3 MBLs for more favored substrates, Km values of 10
5 M
or better were obtained. Some other enzymes from environmental
sources, such as Janthinobacterium lividum BJP-1 (26), Erwinia
carotovora CAR-1 (50), and Caulobacter crescentus CAU-1 (51),
are also notable for their comparably high Km values across the
range of -lactams. However, Rm3 was distinguished frommany
of these by an apparent lack of discrimination against oxyimino-
cephalosporins (e.g., ceftazidime) or 7--methoxy cephalospo-
rins (e.g., cefoxitin), which are poor substrates for the B3 enzymes
CAR-1 andCAU-1, respectively. The kcat/Km values for the hydro-
lysis of these substrates by Rm3 were in line with those for the
other -lactams tested.
Crystal structure of Rm3.Rm3 crystallized in space group P21
with two molecules in the asymmetric unit. A single 1.75-Å reso-
lution data set was collected at the Diamond Light Source syn-
chrotron radiation facility, and phases and an initial electron
density map were calculated by molecular replacement. Data
collection and refinement statistics are given inTable 3. The final
structure contained 268 (chainA) and 269 (chainB) residues, with
electron density not being observed for the 10 (chain A) or 9
(chain B)N-terminal amino acids or for theC-terminal glutamine
residue of either polypeptide chain. We note that the N terminus
of processed Rm3 is formed by a proline-rich sequence (QTPAP
ATPP) that is likely to be unstructured in solution. Of all residues,
96.6% were in the most favored regions of the Ramachandran
plot, with no residues being classified as outliers. The overall
structure (Fig. 3) is that of the MBL superfamily, comprising an
/ fold in which the N- and C-terminal halves of the protein
form central seven- and five-stranded -sheets, respectively, that
are flanked by-helices. The interface of these two sheets provides
the location for the active site. The active-site environment is de-
fined by three loop regions that connect elements of secondary
structure: residues 150 to 164 (loop 1) connecting helix 4 and
strand7, residues 192 to 201 connecting strands9 and10, and
residues 222 to 239 (loop 2) connecting strand 11 and helix 5.
(The BBLnumbering scheme [52] is used throughout this report.)
The presence of disulfide bonds also serves to define the overall
architecture of the Rm3 structure. The processed Rm3 polypep-
tide contains a total of six Cys residues, of which two (residues 256 T
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and 290) form a disulfide bond between helices 5 and 7 that is
common to all B3MBLs of known structure except BJP-1 (53). In
chain A of the current structure, a second disulfide between
Cys208 andCys213 constrains the short loop between strands10
and 11. However, in chain B this disulfide bond is not present,
Cys208 and Cys213 are reduced, and a zinc ion is positioned be-
tween them. This zinc ion is also coordinated by His246 and
Glu249 of an adjacent chain and thus occupies a site that is formed
at the interface of two Rm3 monomers in adjacent asymmetric
units in the crystal. The final pair of Cys residues (positions 32 and
35) also contributes to a further zinc site at the interface between
the two Rm3 molecules present in the crystallographic asymmet-
ric unit, in which zinc coordination is completed by His158 of the
opposing chain and by a crystallographic water molecule. How-
ever, as Rm3 eluted from the size exclusion chromatography col-
umn at a volume consistent with a molecular mass of approxi-
mately 30,000 Da (data not shown), indicating that the protein
likely exists as a monomer in solution, we consider both of these
interface sites to be crystallization artifacts that are unlikely to
exert a physiological function.
Inspection of difference electron density maps from the early
stages of refinement unambiguously identified the presence of two
metal ions in the Rm3 active site. These were refined as zinc ions,
on the basis of the presence of excess zinc in the crystallization
experiment and the absence of other metal ions in the crystal, as
adjudged by the lack of additional peaks in an X-ray fluorescence
excitation spectrum collected at the synchrotron beamline (data
not shown). Both sites were refined to 100% occupancy with B
factors similar to those of the adjacent protein atoms (Table 3).
Consistent with assignment of Rm3 as a member of the B3 MBL
subfamily, the two zinc ions (Zn1 and Zn2) occupy, respectively,
the two binding sites that are defined by conserved residues of the
MBL superfamily, i.e., a trihistidine (Zn1) site formed by His116,
His118, and His196 and an Asp-His-His (Zn2) site formed by
Asp120, His121, and His263 (Fig. 4). In both subunits, the two
zinc ions lie approximately 3.5 Å apart (distances, 3.46 Å and 3.51
Å in chains A and B, respectively) and are connected by a bridging
water molecule (Wat1; which likely exists as a hydroxide ion [54])
that is positioned asymmetrically with respect to the two metal
ions and lies closer to Zn1 (1.81 to 1.90 Å) than to Zn2 (2.04 to
2.11 Å). Metal coordination is completed by a second water mol-
ecule (Wat2) that lies closer to Zn2 but also coordinates Zn1
(Wat2-Zn1 distances, 2.57 and 2.68 Å in chains A and B, respec-
tively) and can thus also be considered to bridge the two metal
ions. As a consequence, both Rm3metal ions are five coordinated.
Five-coordinate metal ion systems can be described using the
structural parameter  [where   (  )/60] to discriminate
between trigonal ( 1) and square ( 0) pyramidal geometries
(55). For the Rm3 Zn1 site, the two angles  and , which repre-
sent distortion from square to trigonal bipyramidal coordination,
can be defined as His116-Zn1-His196 (103.5°) and Wat2-Zn1-
His118 (167.4°), respectively (56), yielding a value for  of 1.07
and indicating that coordination is best described as trigonal bi-
pyramidal. For the Zn2 site,  and  are defined as Wat1-Zn2-
His263 (127.4°) and Wat2-Zn2-Asp120 (155.9°), respectively
(57), giving a value of  of 0.475 and a coordination geometry
intermediate between trigonal bipyramidal and square pyramidal.
In chain B, Wat2 is less well defined by the experimental electron
density but occupies a similar position, with values for  of 0.97 for
the Zn1 site and 0.41 for the Zn2 site. Thus, zinc coordination is
similar in both Rm3 molecules.
Comparison with other B3 MBL structures. The PDBeFold
program (58) was used to generate superpositions of chain B of
Rm3 with the chains B of five other B3 MBLs of known crystal
structure: L1 (PDB accession no. 1SML [59]; root mean square
deviation [RMSD], 1.47 Å over 240 C- atoms), FEZ-1 (PDB
accession no. 1K07 [60]; RMSD, 1.65 Å over 254 C- atoms),
BJP-1 (PDB accession no. 3LVZ [53]; RMSD, 1.73 Å over 251 C-
atoms), AIM-1 (PDB accession no. 4AWY [61]; RMSD, 1.04 Å
over 247 C- atoms), and SMB-1 (PDB accession no. 3VPE [57];
RMSD, 0.87 Å over 245 C- atoms). Thus, the Rm3 structure
most closely resembles those of AIM-1 and SMB-1, consistent
with the closer sequence relationship to these enzymes than to
other structurally characterized B3MBLs. Superposition of the B3
MBL structures (Fig. 5) identifies three regions where there is
variation between the various structures: the extremeN terminus,
the loop connecting helix 4 and strand 7 (sometimes termed
loop 1), and the loop connecting strand 11 and helix 5 (loop 2
[57]). Together these three regions substantially define the active-
site groove in B3MBLs. Notably, the N-terminal region of Rm3 is
poorly defined in the crystal structure, with no electron density
being evident for the proline-rich sequence (QTPAPATPP) that
forms the N terminus of the processed polypeptide after cleavage
of the signal peptide. However, unlike the AIM-1 and SMB-1
TABLE 3 Crystallographic data collection and refinement statistics
Parameter Value(s) for Rm3a
Data collection statistics
Beamline DLS (I04)
Wavelength (Å) 0.9795
Space group P21
Cell dimensions
a, b, c (Å) 45.88, 74.45, 77.46
, ,  (°) 90, 99.48, 90
No. of molecules/asymmetric unit 2
Resolution (Å) 53.32–1.75 (1.78–1.75)
No. of unique reflections 50,630 (2.761)
Redundancy 2.4 (2.3)
Rmerge 0.055 (0.363)
CC1/2 0.997 (0.821)
I/ 9.1 (2.1)
Completeness (%) 97.6 (97.2)
Refinement statistics
Resolution (Å) 53.32–1.75 (1.78–1.75)
No. of reflections 50,593 (2,780)
Rwork/Rfree
b 20.28/22.94 (31.15/32.18)
No. of:
Protein atoms 2,022c/2,029d
Zinc ions 7
Water molecules 302
B factor
Protein 25.58c/26.65d
Zinc 19.38
Water 29.25
RMSD
Bond length (Å) 0.007
Bond angle (°) 1.09
a Statistics for the highest-resolution shell are shown in parentheses.
b Rfree was calculated with 5% of reflections omitted from the refinement.
c Chain A.
d Chain B.
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structures, where a turn preceding the conserved Trp41 forces
relatively short N termini away from the active site, in Rm3, Trp41
is part of an -helix (Fig. 3, 1) that defines one wall of a deeper
active-site groove (Fig. 5). Thus, in this regard Rm3 more closely
resembles BJP-1, where an extended helical N terminus creates an
active site that is much narrower than the active sites of other B3
MBLs of known structure.
Loop 1 (residues 150 to 164) of B3MBLs also contributes sub-
stantially to the active-site architecture. Hydrophobic residues
(Phe156 and Ile162) in loop 1 of L1 were proposed to participate
in binding of substrate (59), but subsequent directed mutagenesis
investigations of L1 (62) and FEZ-1 (63) did not identify these
individual positions to be essential to activity. However, rapid
kinetic experiments (64) have demonstrated that this loop can
adjust its position during the turnover of -lactams by the L1
enzyme, indicating that the structure as a whole may have some
mechanistic role. In addition, both AIM-1 and SMB-1 feature a
Gln at position 157, where models of bound cephalosporin sub-
strates suggest that it may interact with the carboxylate group at
C-7/C-8 formed on hydrolysis of the -lactam amide (57, 61). In
Rm3,Gln157 is present as part of aDPQmotif that is also found in
SMB-1, AIM-1, and THIN-B, and the organization of loop 1
closely resembles that found in AIM-1 and SMB-1 (Fig. 5). By way
of contrast, loop 1 in the L1, FEZ-1, and BJP-1 structures adopts a
conformation more open than is the case here.
Loop 2 (residues 224 to 230) is the third region of variability
between B3MBL structures. In common with AIM-1 and SMB-1,
loop 2 of Rm3 is longer by 2 residues than its equivalent in other
B3 enzymes, with the apex of this loop extending away from the
active site. In L1 and FEZ-1, residues such as Asn225 (FEZ-1) and
Tyr228 (both enzymes) on loop 2 are proposed to contribute to
-lactamhydrolysis through interactionwith theC-7/C-8 carbox-
ylate group of hydrolyzed species (see above) (59, 60, 62). Consis-
tent with the presence of Gln157 on loop 1 (see above), which
could act as a functional replacement for these residues, the equiv-
alent positions of Rm3 loop 2 are occupied by amino acids (Val
and Pro) that are unable to replicate these proposed interactions,
and the conformation of loop 2 is also incompatible with a con-
tribution to -lactam binding and/or hydrolysis. Loop 2 of BJP-1
also differs from the equivalent regions of L1 and FEZ-1, but in
this case it is positioned in a more closed conformation nearer the
zinc center. Taken together, these comparisons indicate that in
both the overall fold and the specific architecture of variable re-
gions (loops 1 and 2) adjacent to the active site, the Rm3 structure
more closely resembles the structures of the mobile B3 enzymes
AIM-1 and SMB-1 than it does the structures of the chromosomal
B3 MBLs L1, FEZ-1, and BJP-1.
In contrast to these clear differences in overall structure be-
tween different B3MBLs, comparison of the respective active sites
indicates that the principal features of the Rm3 metal center are
common between all structurally characterized B3 MBLs. Specif-
ically, all B3 MBLs of known structure feature a binuclear zinc
center with a five-coordinate ion in the Zn2 site and geometry
intermediate between trigonal bipyramidal and square pyramidal,
and (for structures that do not contain bound ligands) the zinc-
zinc distance (3.46 Å and 3.51 Å in Rm3 chains A and B, respec-
tively [see above]) varies between 3.40 and 3.58 Å (for structures
determined at resolutions of between 1.40Å and 1.80Å, compared
to a resolution of 1.75 Å for the structure of Rm3 presented here).
With respect to other B3 enzymes, themain difference in the Rm3
active site is the positioning of the Wat2 water molecule (Fig. 4B
and C), which is notably closer to both Zn1 (distances, 2.57 Å and
2.68 Å in Rm3 chains A and B, respectively) andWat1 (distances,
2.33 Å and 1.96 Å in Rm3 chains A and B, respectively) than is the
case in, e.g., L1 (Wat2-Zn1 andWat2-Wat1 distances, 2.80 Å and
FIG 3 Overall structure of Rm3. Stereo view of Rm3, with the protein backbone being color ramped from blue (N terminus) to red (C terminus). Active-site
residues and disulfide bonds are rendered as sticks (green, carbon atoms; standard (CPK) colors were used for the other atoms). Zinc ions (gray) and water
molecules (red) are shown as spheres. This figure was generated using the PyMOL program (www.pymol.org).
Salimraj et al.
5834 aac.asm.org October 2016 Volume 60 Number 10Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 27, 2016 by UNIV O
F W
ARW
ICK
http://aac.asm
.org/
D
ow
nloaded from
 
3.04 Å, respectively, for the structure with PDB accession no.
1SML).
Implications of Rm3 structure for activity. Despite much ef-
fort, the precise mode of binding of -lactams to the active site of
B3MBLs remains incompletely understood. In fact, only one crys-
tal structure has so far been determined for a B3 MBL complexed
with an antibiotic, that of L1 bound to the hydrolysis product of
the oxacephemmoxalactam (65); docking and quantummechan-
ics/molecular mechanics (QM/MM) approaches have been used
to investigate the interactions of AIM-1 with hydrolyzed cefoxitin
(61). We therefore used superposition of the Rm3 and L1-moxa-
lactam structures to consider possible interactions of hydrolyzed
moxalactam with Rm3 (Fig. 6A and B) in an effort to investigate
determinants of -lactamase activity and the basis for the highKm
values for -lactam hydrolysis by Rm3 that were observed.
Consistent with the ability of Rm3 to hydrolyze most classes of
-lactams, these comparisons imply that the enzyme can replicate
many of the interactions with substrates made by L1 or AIM-1. In
addition to interactions involving the two metal ions (Zn1 with
the C-7/C-8 carbonyl/carboxylate of the -lactam amide and Zn2
with the C-3/C-4 carboxylate of the second ring), the Rm3 active
site contains conserved residues at positions previously implicated
in -lactam binding. In particular, Ser221, a residue that is highly
conserved in B3 MBLs, and Asn223 (Ser or Thr in most other B3
enzymes) are well positioned to contact the C-3/C-4 carboxylate
of bound -lactam. Notably, in the Rm3 crystal structure, the
anticipated positions adopted by the-lactam carboxylate oxygen
atoms are occupied by Wat2 and by a second water molecule
(Wat3) positioned between the Ser221 and Asn223 side chains. As
noted earlier and as has been proposed for AIM-1 (61) and SMB-1
(57), the Gln157 side chain is positioned to contact the C-7/C-8
carboxylate generated by -lactam hydrolysis. Furthermore, the
conserved Trp41 side chain is able to make hydrophobic interac-
tions with the-lactam core. Rm3 is thus able tomake productive
interactions with the core components common across the differ-
ent classes of -lactams.
Given this apparent availability of productive modes of sub-
strate binding, we then considered why Rm3 hydrolyzes -lac-
tams with a relatively low efficiency. Inspection of molecular sur-
faces in the vicinity of the active site (Fig. 6C andD) indicates that,
compared to other B3 enzymes in which the active site sits in a
relatively shallow groove, the Rm3 active site is positioned at the
bottom of a much deeper channel that runs across one side of the
structure.Notably, the extendedN terminus forms onewall of this
cleft in the region that would be expected to form the binding site
for the C-6/C-7 (R1) substituent of -lactams, either requiring
FIG 4 Rm3 active site. (A) Stereo view. Green, carbon atoms; gray, zinc ions; red, water molecules. Standard (CPK) colors were used for the other atoms. The
electron densitymap is 2|Fo| |Fc| ·calc (where Fo and Fc are observed and calculated structure factor amplitudes, respectively, andcalc is the calculated phase),
contoured at 1.5 . (B) Active site of Rm3 showing the position of Wat2 relative to that of Zn1 (distance in black) andWat1 (distance in white). (C) Active site
of L1 (PDB accession no. 1SML [59]) showing the position of Wat2 relative to that of Zn1 and Wat1. This figure was generated using the PyMOL program.
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substrates to adopt specific conformations on binding to avoid
steric clashes or necessitating significant conformational changes
of the enzyme to render the active site more accessible to -lac-
tams, particularly those such as later-generation cephalosporins
(e.g., ceftazidime) with bulky C-7 substituents. Interestingly, for
the B3MBL BJP-1, where in the unliganded enzyme the active site
is occluded by the extended N-terminal -helix, the crystal struc-
ture of a complex with a 4-nitrobenzenesulfonamide inhibitor
showed that inhibitor binding involved displacement of this entire
helix from its position in the native structure in order to make the
active site accessible (53).We thus propose that the highKm values
for Rm3-catalyzed hydrolysis of -lactams arise in large part from
the steric constraints upon substrate binding that are imposed by
the extendedN terminus. It is possible that the additional proline-
rich N-terminal sequence, comprising a further 10 amino acids
that could not be modeled in our final crystal structure, could
impose further restrictions upon substrate binding.
Concluding remarks.The increasing availability of sequence in-
formation from genomic and metagenomics projects has begun to
establish the extent to which antibiotic resistance genes are distrib-
uted in the wider environment. It is now clear thatMBLs, and the B3
subclass in particular, are frequently present on the chromosomes of
environmental organisms that include, but are not limited to, oppor-
tunist human pathogens, such as S. maltophilia or E. meningosepti-
cum. Accumulating evidence shows that the antibiotic era has
been characterized by repeated instances of the mobilization of
resistance determinants from environmental species, such as
Kluyvera or Shewanella spp., into clinically significant pathogens
FIG 5 Comparison of Rm3 with other B3 MBLs. The superposition of Rm3 structure upon the structures of other B3 MBLs is shown. (A to D) Overall fold of
Rm3 (chain A; color-ramped from N (blue) to C (red) terminus (A), SMB-1 (PDB accession no. 3VPE [57]) (B), L1 (PDB accession no. 1SML [59]) (C), and
BJP-1 (PDB accession no. 3LVZ [53]) (D). Residues discussed in the text are rendered as sticks. This figure was generated using the PyMOL program.
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and their subsequent global dissemination on multiresistance
plasmids. It is also becoming apparent that exposure to detergents
and biocides, as well as antibiotics, may also be implicated in the
mobilization of resistance genes and coselection of multiresis-
tance elements. In this work, we describe the properties of the
product of a novel resistance gene, blaRm3, thatwas identified from
an environment with high levels of biocide exposure.
blaRm3 encodes a B3 MBL that is active against most -lactam
classes in vitro and is able to reduce the cephalosporin susceptibil-
ity of recombinant E. coli, thus replicating characteristics of en-
zymes of clinical importance. Sequence-based phylogeny indi-
cates that Rm3 is representative of a distinct clade of B3MBLs that
differs from the L1 and FEZ-1/GOB groups (Fig. 2). It is likely
that, given their occurrence in environmental samples from sites
that differ greatly in their geographical location and level of hu-
man impact, these enzymes have a wide distribution in the envi-
ronment. With increasing use of broad-spectrum -lactams and
the associated increase in selection pressure, there is thus consid-
erable potential for future mobilization of MBLs of this type into
the clinic. The structure of Rm3 demonstrates an overall resem-
blance to the structures of mobilized AIM-1 and SMB-1 enzymes
and provides a basis for both the -lactamase activity of Rm3 and
the limited efficiency with which it hydrolyzes most substrates.
However, the architecture of the active site that is created by the
extendedN terminus distinguishes Rm3 from other B3MBLs that
have been studied so far, suggesting both that (as has been sug-
gested for other B3 MBLs [50]) -lactams may not necessarily be
the natural substrates for these enzymes and that there is a capacity
for -lactamase activity to be improved by mutation. Future ex-
periments will investigate these possibilities.
FIG 6 Proposed interactions of Rm3 with substrates. (A) Crystal structure of L1 bound to hydrolyzed moxalactam (PDB accession no. 2AIO [65]). (B)
Superposition of hydrolyzed moxalactam from the structure with PDB accession no. 2AIO on structure of Rm3 (this work). Note that superposition places the
moxalactamC-4 carboxylate overWat2 andWat3,N-5 and theC-4 carboxylate in proximity to Zn2, and theC-8 carboxylate close to Zn1. (C andD) Space-filling
representations of the L1 complex (PDB accession no. 2AIO) and Rm3 structure (this work) with boundmoxalactam superposed in stick form. The extended N
terminus of Rm3 (residues 32 to 43) is highlighted in pale green. This figure was generated using the PyMOL program.
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